The focus of the industry is living organisms, and the strict monitored standards make it a unique consideration for business executives. These features make the industry an ideal platform for innovation. They have resulted in major breakthroughs in biofuels, agricultural yields and life-saving pharmaceuticals.
Biotech startups have a myriad of options for revenue generation strategies, with most choosing either a technology partnering or an asset creation and out-licensing strategy. Technology partnering can result in more revenue and reduce financial risk, while asset creation and outlicensing strategies can yield significantly more returns. A increasing number of biotechs at the research stage employ the hybrid approach, which combines these two approaches.
Those who opt for an approach to development that is oriented towards product will succeed commercially when they are able to get their pipeline to the right stage and then attract a major pharmaceutical partner or an investor with a large sum of https://genotec-frankfurt.de/bio-pharmazeutika-werden-zu-einer-anerkannten-form-der-alternativmedizin/ money. It can be a costly option. It is crucial to consider the balance between opportunistic strategies in taking advantage of outside resources and the right scientific decisions regarding homegrown projects.
Alternately, the „platform” model can provide an alternative route to earning revenue. It is a less expensive alternative to the product-oriented approach however, it comes with substantial risk. In this model, a biotech owns and develops its platform technology, before working with large pharma companies to develop a portfolio of drug discovery projects that specifically target diseases (i.e. disease that is x within biology and y). Advinus Therapeutics, among others, have adopted this approach.